AMENDMENT #1 TO CONSULTING AGREEMENT BETWEEN KARYOPHARM THERAPEUTICS INC. AND JATIN SHAH, M.D.
Exhibit 10.5
AMENDMENT #1 TO
CONSULTING AGREEMENT BETWEEN
AND XXXXX XXXX, M.D.
THIS AMENDMENT #1 (“Amendment”) amends the Consulting Agreement between Karyopharm Therapeutics Inc. (“Karyopharm”) and Xxxxx Xxxx, M.D. (“Consultant”) with an Effective Date of the 1st day of March 2022, (the “Agreement”). This Amendment shall be effective as of March 21, 2022 (the “Amendment 1 Effective Date”).
WHEREAS, the Consultant and the Company agree to amend the description of services provided by the Consultant; and
WHEREAS, the Parties wish to amend the hours of services to be provided by Consultant.
NOW THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:
Exhibits. Exhibit A is hereby deleted in its entirety, and replaced with A-1, attached hereto, which shall be effective as of the Amendment 1 Effective Date.
IN WITNESS WHEREOF, this Amendment is effective as of the Amendment #1 Effective Date.
KARYOPHARM THERAPEUTICS INC. XXXXX XXXX, M.D.
/s/ Xxxxxx Rotman_____________________ /s/ Xxxxx Sha___________________
By: Xxxxxx Xxxxxx By:
Title: Chief People & Corporate Engagement Officer Title:
1
Exhibit A-1
DESCRIPTION OF SERVICES
The Consultant shall provide assistance to the Company, as from time to time reasonably requested by the Chief Executive Officer or his designees limited to institutional knowledge relating to myeloma specific matters for internal purposes only.
The Consultant shall devote up to 15 hours per month to providing Services.
2